The U.S. Food and Drug Administration approved Scynexis Inc.’s Brexafemme (ibrexafungerp tablets) as the first oral non-azole treatment for vaginal yeast infections.

Pfizer is expanding the company’s presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and the lead antifungal compound Fosmanogepix (APX001).

Scynexis Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for oral ibrexafungerp for the treatment of vulvovaginal candidiasis.

The deadly fungal infection Candida auris reared its head iin a Los Angeles healthcare facility and could be related to Covid-19 cases through the conservation of personal protective equipment strategies. Amplyx Pharmaceuticals is working to develop a first-line treatment for patients with invasive fungal infections caused by Candida.

Jersey City, N.J.-based SCYNEXIS announced positive results from the biotechnology company’s second interim efficacy analysis of the Phase III open-label FURI study.

Cidara Therapeutics Inc. announced that data from studies of the biotechnology company’s lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR to be held in Houston from Feb. 20-24.

Bayer agreed to sell the German drugmaker’s established prescription dermatology brands to Denmark’s Leo Pharma.

Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.

Almirall SA announced it plans to halt all research into P3058 (onychomycosis) and P3073 (nail psoriasis) in the U.S. However, clinical trials planned in Europe will continue as scheduled.

A rare fungus that can cause drug-resistant infections has been found in around 200 patients in more than 55 hospitals across Britain, health officials said.